National Breast and Cervical Cancer Early Detection Program (NBCCEDP)

The National Breast and Cervical Cancer Early Detection Program is a CDC program that funds breast and cervical cancer screening — mammograms, Pap tests, HPV tests, and clinical breast exams — for low-income, uninsured, and underinsured women across all 50 states, the District of Columbia, five U.S. territories, and 12 tribal organizations. Created by the Breast and Cervical Cancer Mortality Prevention Act of 1990 and codified at 42 U.S.C. §§ 300k–300n-5, NBCCEDP fills a critical gap: most low-income women without insurance cannot afford cancer screening, and early detection is the single most effective intervention for reducing breast and cervical cancer mortality. The program has provided screening services to over 6 million women and diagnosed hundreds of thousands of cancers and precancerous conditions since its inception. Women detected with cancer through NBCCEDP become automatically eligible for Medicaid treatment coverage under a companion program — see Title X family planning for the parallel CDC reproductive health services program, and maternal and child health block grants for the broader federal investment in women's and children's health.

Current Law (2026)

Legal Authority

• 42 U.S.C. § 300k — Establishment: the Secretary, acting through the CDC Director, may make competitive grants to states for programs providing breast and cervical cancer screening; states must target screening to low-income women and must comply with quality standards set by the Secretary; grants fund mammograms, Pap tests, and follow-up diagnostic procedures
• 42 U.S.C. § 300l — Matching funds: states must agree to provide non-federal matching funds to receive NBCCEDP grants; the matching requirement ensures states have skin in the game and prevents federal funds from wholly supplanting state cancer screening investment
• 42 U.S.C. § 300l-1 — Medicaid linkage requirement: the Secretary may not make a grant to a state unless the state's Medicaid plan covers treatment for women with breast or cervical cancer who were screened through the program; this is the statutory basis for the CDC-Medicaid link that provides treatment coverage to women diagnosed through NBCCEDP; the corresponding Medicaid provision was created separately to give states a mandatory Medicaid pathway for NBCCEDP-diagnosed cancers
• 42 U.S.C. § 300m — Quality standards: states receiving grants must provide services consistent with prevailing medical standards for breast and cervical cancer screening; services must be provided by licensed or certified providers; states must establish quality assurance mechanisms; the Secretary sets minimum standards
• 42 U.S.C. § 300n — Priority for low-income women: states must give priority in providing services to low-income women; additional requirements cover outreach to underserved communities, data collection, and coordination with other programs
• 42 U.S.C. § 300n-4a — Supplemental grants: the Secretary may make additional competitive grants to states for preventive health services supplemental to routine screening — including case management, patient navigation, and health education related to breast and cervical cancer

The CDC-Medicaid Treatment Connection

One of NBCCEDP's most important features is the connection between screening and treatment. Finding cancer is only valuable if the patient can receive treatment — but uninsured low-income women often cannot afford cancer treatment. Congress solved this with the Breast and Cervical Cancer Prevention and Treatment Act of 2000, which authorized states to cover treatment through Medicaid for women who:

1. Were screened through the NBCCEDP program, and
2. Are diagnosed with breast or cervical cancer or a precancerous condition

This provision (which is implemented through the Medicaid statute, complementing § 300l-1 here) creates a full pathway from screening to diagnosis to treatment for low-income uninsured women. All 50 states have adopted this Medicaid option. The combination of NBCCEDP screening + Medicaid treatment coverage means that a woman without insurance can receive free mammography and, if cancer is found, full Medicaid-covered cancer treatment.

Who the Program Serves

NBCCEDP targets its services to women who are:

• Uninsured or underinsured (no insurance or insurance without preventive care coverage)
• At or below 250% of the federal poverty level
• Of screening age — 40 to 64 for breast cancer; 21 to 64 for cervical cancer (varies by guideline updates)

The program historically has not served all eligible women because funding is insufficient to serve the full eligible population. CDC estimates that the program reaches roughly 10–15% of the eligible population. Wait lists are common. State programs must prioritize the lowest-income and oldest women among those eligible.

How It Affects You

If you are uninsured or underinsured and need a mammogram or Pap test: To find your state's NBCCEDP program, call 1-800-CDC-INFO (1-800-232-4636) or visit cdc.gov/cancer/nbccedp and search by state. Basic eligibility: you must be at or below 250% of the federal poverty level (about $37,650/year for an individual in 2025), be uninsured or have insurance that doesn't cover preventive screening, and be in the age range for screening — 40 to 64 for breast cancer (mammogram and clinical breast exam), 21 to 64 for cervical cancer (Pap test and HPV test). Income eligibility is verified by self-attestation in many states — you don't need to produce years of tax returns. The program covers the screening tests and follow-up diagnostic services (such as a diagnostic mammogram or colposcopy if initial results are abnormal). Be aware: the program is funded to serve only about 10–15% of eligible women. Many state programs have wait lists — call early, don't wait until you feel symptoms.

If you are diagnosed with breast or cervical cancer through the program: You automatically become eligible for Medicaid coverage of your cancer treatment — regardless of whether you would otherwise qualify for Medicaid under normal income or categorical rules. All 50 states have adopted this pathway. The Medicaid coverage begins at the point of diagnosis and covers the full range of cancer treatment: surgery, chemotherapy, radiation, and follow-up care. You do not need to re-apply for Medicaid through the standard process; the NBCCEDP program should initiate the enrollment. If you have any difficulty accessing treatment coverage, contact your state's Medicaid office or a patient navigator at the diagnosing facility.

If you recently lost employer health insurance and are approaching your first mammogram: If you're between 40 and 64 and your income drops after losing coverage (or if COBRA is unaffordable), NBCCEDP could cover your first screening while you establish new coverage. The program is intended as a bridge for women who would otherwise go without screening — not as a long-term substitute for insurance. Check both the NBCCEDP program for your state and whether you qualify for ACA marketplace enrollment through a Special Enrollment Period (loss of coverage is a qualifying event). Prioritizing a cancer screening while pursuing insurance is not an either/or choice.

If you have a family history of breast or ovarian cancer: NBCCEDP covers standard screening for income-eligible women but does not fund genetic testing (BRCA1/BRCA2 mutation testing) or enhanced screening protocols for high-risk individuals. If you have a first-degree relative with breast or ovarian cancer and are income-eligible for the program, you can still use NBCCEDP for standard mammography — but discuss your family history with the provider to understand whether you need additional monitoring beyond what the program funds. Some state programs have supplemental funding or referral pathways for high-risk women.

State Variations

All 50 states participate in NBCCEDP, but program capacity varies by funding and state budget. States with higher state-level matching funds can serve more women. Some states supplement NBCCEDP with state-funded screening programs, expanding the age range or income eligibility beyond federal program requirements. Tribal organizations and U.S. territories have their own grant-funded programs administered separately from state programs.

Pending Legislation

No major structural changes pending as of April 2026. NBCCEDP funding has been flat or modestly increased for many years. The gap between the program's capacity and the eligible population — serving roughly 10-15% of eligible women — has been a persistent advocacy concern. Expanding program capacity to cover more eligible women would require significantly higher appropriations.

Recent Developments

• USPSTF lowered mammography screening start age to 40 (2024) — NBCCEDP eligibility expanded: The U.S. Preventive Services Task Force finalized updated breast cancer screening guidelines in 2024, recommending that women start mammography screening at age 40 (down from 50 for average-risk women in the 2016 guidelines). This change required NBCCEDP programs to update their eligibility criteria — programs that had primarily served women 40–64 already often covered women beginning at 40, but the new guideline creates demand from women in their 40s who previously may not have been systematically encouraged to screen. NBCCEDP program grantees have updated their outreach and enrollment protocols to align with the new USPSTF recommendation.
• MAHA agenda and NBCCEDP: RFK Jr.'s "Make America Healthy Again" impact on cancer programs: HHS Secretary Robert F. Kennedy Jr.'s MAHA agenda has focused primarily on nutrition, food additives, and environmental exposures rather than on cancer screening programs specifically. However, MAHA's skepticism of some established preventive medicine approaches and its questioning of pharmaceutical industry relationships with federal health agencies created some uncertainty about CDC screening program priorities. NBCCEDP, which is administered by CDC's Division of Cancer Prevention and Control, has maintained its mission focus; no MAHA-driven changes to breast or cervical cancer screening recommendations have been proposed as of April 2026.
• HPV vaccine uptake and cervical cancer screening decline — NBCCEDP tracking outcomes: The HPV vaccine (Gardasil), which prevents the primary cause of cervical cancer, has been available since 2006 and is recommended for adolescents. As the vaccinated generation ages into the NBCCEDP-eligible population (40+), cervical cancer incidence rates should decline — already visible in data showing lower rates among younger women. However, HPV vaccine uptake among adolescents remains below recommended levels in many states (particularly in rural and lower-income areas), meaning the full prevention benefit won't be realized for decades. NBCCEDP Pap and HPV co-testing remains essential for unvaccinated women and women vaccinated after earlier HPV exposures.
• COVID screening backlog cleared — but late-stage diagnoses increasing: The 2020 COVID-related collapse in preventive care visits resulted in millions of missed mammograms and Pap tests nationally. Studies published in 2023-2024 show measurable increases in late-stage breast and cervical cancer diagnoses attributable to the 2020 screening backlog — the full consequences of missed screenings are now appearing as diagnoses in women whose cancers progressed undetected. NBCCEDP programs have refocused on outreach to women who missed screenings during the pandemic; CDC and NCI have funded studies to quantify the long-term mortality impact of the screening drop.